Brian Druker and Charles Sawyers receive the 2011 ASCI/Stanley J. Korsmeyer Award.
作者信息
Claiborn Kathryn
出版信息
J Clin Invest. 2011 Apr;121(4):1227-8. doi: 10.1172/jci57942.
Abstract
摘要
相似文献
1
Brian Druker and Charles Sawyers receive the 2011 ASCI/Stanley J. Korsmeyer Award.布莱恩·德鲁克和查尔斯·索耶斯荣获2011年美国临床研究学会/斯坦利·J·科斯迈耶奖。
J Clin Invest. 2011 Apr;121(4):1227-8. doi: 10.1172/jci57942.
2
Attacking cancer at its root.从根源上攻克癌症。
Cell. 2009 Sep 18;138(6):1051-4. doi: 10.1016/j.cell.2009.09.002.
3
Investigator profile. Brian J. Druker, M.D. Interview by Vicki P. Glaser.研究者简介。医学博士布莱恩·J·德鲁克。由维基·P·格拉泽采访。
J Hematother Stem Cell Res. 2001 Dec;10(6):721-4. doi: 10.1089/152581601317210818.
4
Imatinib (Gleevec) as a paradigm of targeted cancer therapies.伊马替尼（格列卫）作为靶向癌症治疗的范例。
Keio J Med. 2010;59(1):1-3. doi: 10.2302/kjm.59.1.
5
Part I: Milestones in personalised medicine--imatinib.第一部分：个性化医疗的里程碑——伊马替尼
Lancet Oncol. 2008 Jun;9(6):600. doi: 10.1016/S1470-2045(08)70152-9.
6
[Treatment of chronic myeloid leukemia with imatinib. A case of translational medicine].
Medicina (B Aires). 2010;70(3):293-6.
7
Treatment for chronic myelogenous leukemia: the long road to imatinib.慢性粒细胞白血病的治疗：通往伊马替尼的漫长之路。
J Clin Invest. 2007 Aug;117(8):2036-43. doi: 10.1172/JCI31691.
8
David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies.
J Clin Oncol. 2003 Dec 1;21(23 Suppl):239s-245s. doi: 10.1200/JCO.2003.10.589.
9
Perspectives on the development of imatinib and the future of cancer research.伊马替尼的发展前景与癌症研究的未来
Nat Med. 2009 Oct;15(10):1149-52. doi: 10.1038/nm1009-1149.
10
Shifting paradigms: the seeds of oncogene addiction.范式转变：癌基因成瘾的根源
Nat Med. 2009 Oct;15(10):1158-61. doi: 10.1038/nm1009-1158.
Zotero 插件